JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

[Retrospective study of role of neoadjuvant rectal scores in evaluating the 10-year disease-free survival of patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy followed by surgery]

  • 0Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery +

|

June 20, 2024

|

June 20, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The neoadjuvant rectal (NAR) score reliably predicts 10-year disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy. Higher NAR scores indicate a greater risk of recurrence and metastasis, outperforming tumor regression grade scores.

Area Of Science

  • Oncology
  • Gastroenterology
  • Radiotherapy
  • Surgical Oncology

Context

  • Locally advanced rectal cancer (LARC) requires multimodal treatment, including neoadjuvant chemoradiotherapy (nCRT).
  • Accurate prognostication is crucial for tailoring treatment and managing patient expectations.
  • The neoadjuvant rectal (NAR) score is a potential tool for predicting outcomes after nCRT.

Purpose

  • To evaluate the correlation between the NAR score and long-term disease-free survival (DFS) in LARC patients.
  • To compare the predictive performance of the NAR score against the tumor regression grade (TRG) score for recurrence and metastasis.
  • To identify independent predictors of 10-year DFS in this patient cohort.

Summary

  • A retrospective analysis of 487 LARC patients treated with nCRT and surgery was conducted.
  • The 10-year DFS rates varied significantly with NAR scores (<8: 85.1%, 8-16: 80.5%, >16: 66.4%; P<0.001).
  • The NAR score demonstrated superior predictive accuracy for 10-year recurrence and metastasis (AUC=0.67) compared to the TRG score (AUC=0.54).

Impact

  • The NAR score is a reliable and superior predictor of long-term DFS in LARC patients undergoing nCRT.
  • This finding can aid in risk stratification and personalized treatment planning for rectal cancer.
  • The study highlights the importance of the NAR score in predicting oncological outcomes beyond 10 years.